RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Dbv Technologies Stock

Dbv Technologies ROE 2024

Dbv Technologies ROE

-0.52

Ticker

DBV.PA

ISIN

FR0010417345

WKN

A1JWB7

In 2024, Dbv Technologies's return on equity (ROE) was -0.52, a 4.96% increase from the -0.49 ROE in the previous year.

Dbv Technologies Aktienanalyse

What does Dbv Technologies do?

DBV Technologies SA (DBV) is a biopharmaceutical company specializing in the development of therapies for allergic diseases. The company was founded in 2002 by Pierre-Henri Benhamou in France. Its objective is to set new standards in the treatment of allergies through innovative approaches. DBV's business model is based on the research and development of products based on epicutaneous tests (application of allergens on the skin). This alternative method to the common oral immunotherapy (OIT) treats allergic reactions using special patch products. These patches contain the allergens that trigger an allergic reaction in the patient. Through continuous contact with the allergens, the body's defense mechanisms learn that there is no threat and suppress the allergic reaction. DBV offers two products based on epicutaneous tests: Viaskin Peanut and Viaskin Milk. Viaskin Peanut is DBV's first product for the treatment of peanut allergies, while Viaskin Milk is the next product in the pipeline. Viaskin Peanut is a patch that contains a microdose of peanut protein. It is applied to the patient's skin, gradually familiarizing the immune system with the allergen and reducing allergic reactions. The patch can also be used in children, making it an important innovation in the treatment of peanut allergies. Viaskin Milk is also a patch that contains specific proteins found in milk. This patch aims to revolutionize the treatment of milk intolerances, as there are currently no specific therapies for this type of allergy. Again, this is an epicutaneous test. DBV has previously entered into several partnerships with other companies. This includes a collaboration with Nestle to further expand the potential of epicutaneous test products. Networking with insurers and health insurance companies is also an important strategic step in establishing the use of epicutaneous test products in practice. The company is particularly active in Europe and the USA. Its IPO took place in 2012. In 2017, DBV became the first French drug manufacturer to receive approval from the European Medicines Agency (EMA) for Viaskin Peanut. DBV Technologies SA has great potential in the development of epicutaneous products for long-term treatment of allergies. The company has achieved promising results in a short period of time and has established itself as an innovative player in the field of allergology. Dbv Technologies ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Dbv Technologies's Return on Equity (ROE)

Dbv Technologies's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Dbv Technologies's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Dbv Technologies's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Dbv Technologies’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Dbv Technologies stock

What is the ROE (Return on Equity) of Dbv Technologies this year?

The ROE of Dbv Technologies this year is -0.52 undefined.

How has the Return on Equity (ROE) of Dbv Technologies developed compared to the previous year?

The ROE of Dbv Technologies has increased by 4.96% increased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Dbv Technologies?

A high ROE indicates that Dbv Technologies generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Dbv Technologies?

A low ROE can indicate that Dbv Technologies is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Dbv Technologies affect the company?

A change in ROE (Return on Equity) of Dbv Technologies can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Dbv Technologies?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Dbv Technologies?

Some factors that can influence Dbv Technologies's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Dbv Technologies pay?

Over the past 12 months, Dbv Technologies paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Dbv Technologies is expected to pay a dividend of 0 USD.

What is the dividend yield of Dbv Technologies?

The current dividend yield of Dbv Technologies is .

When does Dbv Technologies pay dividends?

Dbv Technologies pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Dbv Technologies?

Dbv Technologies paid dividends every year for the past 0 years.

What is the dividend of Dbv Technologies?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Dbv Technologies located?

Dbv Technologies is assigned to the 'Health' sector.

Wann musste ich die Aktien von Dbv Technologies kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Dbv Technologies from 9/22/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/22/2024.

When did Dbv Technologies pay the last dividend?

The last dividend was paid out on 9/22/2024.

What was the dividend of Dbv Technologies in the year 2023?

In the year 2023, Dbv Technologies distributed 0 USD as dividends.

In which currency does Dbv Technologies pay out the dividend?

The dividends of Dbv Technologies are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Dbv Technologies stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Dbv Technologies

Our stock analysis for Dbv Technologies Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Dbv Technologies Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.